{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroblastoma&page=2", "query": { "condition": "Neuroblastoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroblastoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T07:48:41.178Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00066599", "title": "Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neuroblastoma", "Neutropenia", "Sarcoma" ], "interventions": [ { "name": "voriconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "2 Years to 11 Years" }, "enrollment_count": null, "start_date": "2003-06", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-05-22T07:48:41.178Z", "location_count": 7, "location_summary": "Orange, California • San Diego, California • Bethesda, Maryland + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066599" }, { "nct_id": "NCT02035137", "title": "131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "131I-MIBG", "type": "RADIATION" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "New Approaches to Neuroblastoma Therapy Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "2 Years to 30 Years" }, "enrollment_count": 114, "start_date": "2014-07", "completion_date": "2021-02-26", "has_results": true, "last_update_posted_date": "2022-06-08", "last_synced_at": "2026-05-22T07:48:41.178Z", "location_count": 13, "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02035137" }, { "nct_id": "NCT02439788", "title": "3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "GINAKIT Cells", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "GENETIC" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 0, "start_date": "2017-08", "completion_date": "2030-10", "has_results": false, "last_update_posted_date": "2017-06-14", "last_synced_at": "2026-05-22T07:48:41.178Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02439788" }, { "nct_id": "NCT02982941", "title": "Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Rhabdomyosarcoma", "Osteosarcoma", "Ewing Sarcoma", "Wilms Tumor", "Desmoplastic Small Round Cell Tumor" ], "interventions": [ { "name": "Enoblituzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "35 Years", "sex": "ALL", "summary": "1 Year to 35 Years" }, "enrollment_count": 25, "start_date": "2016-12", "completion_date": "2019-05-22", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-05-22T07:48:41.178Z", "location_count": 6, "location_summary": "Palo Alto, California • Bethesda, Maryland • Philadelphia, Pennsylvania + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02982941" }, { "nct_id": "NCT02307630", "title": "PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Melanoma", "Neuroblastoma", "Sarcoma" ], "interventions": [ { "name": "124I-Humanized 3F8", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "3 Years to 90 Years" }, "enrollment_count": 7, "start_date": "2014-11", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-05-22T07:48:41.178Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02307630" }, { "nct_id": "NCT02095132", "title": "Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Central Nervous System Embryonal Tumor With Rhabdoid Features", "Central Nervous System Embryonal Tumor, Not Otherwise Specified", "Central Nervous System Ganglioneuroblastoma", "Embryonal Tumor With Multilayered Rosettes, C19MC-Altered", "Pineoblastoma", "Primary Central Nervous System Neoplasm", "Recurrent Childhood Central Nervous System Embryonal Neoplasm", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Rhabdomyosarcoma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Rhabdomyosarcoma" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 76, "start_date": "2014-03-28", "completion_date": "2023-06-30", "has_results": true, "last_update_posted_date": "2023-09-26", "last_synced_at": "2026-05-22T07:48:41.178Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02095132" }, { "nct_id": "NCT05012098", "title": "Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Olfactory Neuroblastoma", "Esthesioneuroblastoma", "Neoplasm of the Nasal Cavity" ], "interventions": [ { "name": "Bintrafusp alfa/M7824", "type": "DRUG" }, { "name": "Ibuprofen", "type": "DRUG" }, { "name": "PET scan", "type": "DIAGNOSTIC_TEST" }, { "name": "CT scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Tumor tissue biopsy", "type": "PROCEDURE" }, { "name": "Brain MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "Dotate scan", "type": "DIAGNOSTIC_TEST" }, { "name": "PET FDG scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Nuclear bone scan", "type": "DIAGNOSTIC_TEST" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2022-06-21", "completion_date": "2024-07-09", "has_results": true, "last_update_posted_date": "2025-08-08", "last_synced_at": "2026-05-22T07:48:41.178Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05012098" }, { "nct_id": "NCT00898638", "title": "Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "biologic sample preservation procedure", "type": "OTHER" }, { "name": "medical chart review", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8000, "start_date": "2003-02-13", "completion_date": "2050-12", "has_results": false, "last_update_posted_date": "2025-10-28", "last_synced_at": "2026-05-22T07:48:41.178Z", "location_count": 4, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00898638" }, { "nct_id": "NCT00003883", "title": "Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "fluconazole", "type": "DRUG" }, { "name": "itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 578, "start_date": "1998-10", "completion_date": "2002-07", "has_results": false, "last_update_posted_date": "2010-04-02", "last_synced_at": "2026-05-22T07:48:41.178Z", "location_count": 2, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003883" }, { "nct_id": "NCT00969722", "title": "A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Refractory Neuroblastoma" ], "interventions": [ { "name": "MAb-3F8", "type": "BIOLOGICAL" }, { "name": "Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)", "type": "BIOLOGICAL" }, { "name": "13-cis-Retinoic Acid", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "United Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Months", "maximum_age": "13 Years", "sex": "ALL", "summary": "18 Months to 13 Years" }, "enrollment_count": 1, "start_date": "2009-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-03-08", "last_synced_at": "2026-05-22T07:48:41.178Z", "location_count": 15, "location_summary": "Phoenix, Arizona • San Diego, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00969722" } ] }